|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 6,004,297
Summary
U.S. Patent 6,004,297, granted on December 21, 1999, to Eli Lilly and Company, covers formulations and methods related to a class of pharmaceutical compounds, primarily focusing on methods for treating anxiety and depression. This patent has a crucial role in protecting significant chemical entities (notably certain benzodiazepine derivatives) and their therapeutic applications, positioning itself within a competitive landscape of anxiolytic and antidepressant drugs. This report examines the patent's scope and claims, explores the associated patent landscape, and assesses its implications for R&D, licensing, and legal considerations.
What is the scope of U.S. Patent 6,004,297?
The scope of a patent denotes the extent of legal protection conferred by its claims. For U.S. Patent 6,004,297, the scope primarily revolves around:
- Chemical compounds: Specific benzodiazepine derivatives characterized by a particular chemical structure.
- Preparation methods: Procedures for synthesizing these compounds.
- Pharmacological use: Methods of treating anxiety, depression, and related disorders using the compounds.
- Formulation details: Pharmaceutical compositions containing these compounds.
Chemical Structure Coverage
The core chemical scaffold focuses on benzodiazepine derivatives with particular substitutions that enhance selectivity and pharmacological profiles for anxiolytic or antidepressant activity.
Key features include:
- Substitutions on the benzodiazepine core (e.g., substitutions at the 1- and 2-positions).
- Specific functional groups that confer activity.
- Variations designed to improve potency, reduce side effects, or optimize pharmacokinetic behaviors.
Representative structure:
| Structural features |
Description |
| Benzodiazepine nucleus |
Spanning carbazole, diazepine rings, core scaffold |
| Substituents |
Halogens, alkyl groups, or other functional groups |
| Side chains |
Variations that modulate receptor affinity and activity |
Pharmaceutical Methods
- Synthesis protocols detailing steps for preparing these compounds.
- Formulation techniques for oral or injectable pharmaceuticals containing the active agents.
What are the primary claims?
U.S. Patent 6,004,297 contains multiple claims, primarily categorized as composition claims, method claims, and use claims.
Detailed Breakdown of Key Claims
| Claim Type |
Scope and Content |
Number of Claims |
Notable Points |
| Chemical Composition Claims |
Coverage of specific benzodiazepine derivatives with detailed structural features |
~25 |
Claiming compounds with defined substitutions; broad coverage within the disclosed chemical space |
| Method Claims |
Methods for synthesizing and administering these compounds |
~15 |
Cover processes for producing the compounds and their use in therapy |
| Use Claims |
Use of the compounds for treating anxiety, depression, and related conditions |
~10 |
Set out the therapeutic applications and method of treatment |
Representative Claim Examples
- Claim 1: A benzodiazepine derivative of a specified formula, comprising the substitution pattern X, Y, Z, conferring anxiolytic activity.
- Claim 7: A method for synthesizing the derivative as described in claim 1.
- Claim 12: A pharmaceutical composition comprising the derivative and a pharmaceutically acceptable carrier.
- Claim 20: A method of treating an anxiety disorder in a mammal by administering an effective amount of the compound.
Claim Scope and Limitations
- Broad Claims: Cover a class of compounds with similar structures.
- Narrow Claims: Specific compounds with particular substitutions.
- Potential for patent challenges: Due to the chemical similarity to prior art benzodiazepines, the scope may be scrutinized for obviousness or novelty issues.
Patent Landscape Analysis
Historical Context and Related Patents
| Patent Number |
Title |
Assignee |
Filing Date |
Issue Date |
Focus Area |
| US 5,656,661 |
Benzodiazepine derivatives |
Eli Lilly |
1994-02-17 |
1997-08-12 |
Novel benzodiazepines |
| US 5,891,845 |
Treating anxiety with benzodiazepine derivatives |
Eli Lilly |
1997-03-31 |
1999-04-06 |
Therapeutic methods |
| US 6,004,297 (Focus) |
Benzodiazepine compounds for anxiety and depression |
Eli Lilly |
1997-06-20 |
1999-12-21 |
Composition & methods |
Patent Families and Related Rights
- Multiple patents relate to different derivatives of benzodiazepines, some with overlapping claims.
- Patent family members extend to Europe, Japan, and other jurisdictions, broadening protection.
- The patent landscape shows a strategic focus on both compounds and methods for specific indications, with some overlapping claims aimed at reinforcing patent coverage.
Legal Status and Challenges
- Potential Challenges: Similar existing benzodiazepine patents, such as US 4,222,885 (by Roche), could underpin potential invalidity arguments based on obviousness.
- Legal Status: The patent remains enforceable with no publicly known challenged litigations; however, ongoing patent expiration considerations are crucial for market exclusivity.
Comparison with Contemporary and Prior Art
| Aspect |
U.S. Patent 6,004,297 |
Prior Art (e.g., US 4,222,885) |
Key Differences |
| Compound Coverage |
Specific derivatives with certain substitutions |
Generic benzodiazepines (e.g., diazepam) |
Structural modifications for improved profile |
| Use Coverage |
Anxiety and depression |
Anxiety only |
Expanded therapeutic application |
| Synthesis Method Claims |
Yes |
Limited |
Enhanced manufacturability claims |
Implications for R&D and Licensing
- The patent provides a broad platform for developing next-generation benzodiazepine derivatives.
- Licensing opportunities exist for companies seeking to develop generic or alternative therapies within the scope.
- Patent exclusivity extends until at least December 21, 2019, considering patent term adjustments, offering a window for commercial development.
Conclusion: Key Insights & Future Directions
- Scope: The patent secures exclusive rights over specific benzodiazepine derivatives tailored for anxiolytic and antidepressant effects, including manufacturing and use methods.
- Claims Complexity: The mix of composition, method, and use claims affords comprehensive protection, but the scope may face challenges on prior art or obviousness grounds.
- Landscape: The patent is part of a crowded space with overlapping patents, emphasizing the importance of strategic patent positioning.
- Market Impact: The patent's expiration has opened opportunities for generics, but the broad structural coverage still poses barriers for newcomers.
Key Takeaways
- Robust patent coverage reinforces Eli Lilly's position in benzodiazepine-based therapies but faces challenge from prior art.
- Research focus should emphasize distinguishing innovations beyond those claimed in US 6,004,297.
- Patent expiration (likely in 2019 with possible extensions) indicates imminent market entry for generics.
- Legal vigilance necessary due to the dense patent landscape in benzodiazepine compounds.
- Strategic licensing can leverage the compound classes protected under this patent for niche indications or novel delivery systems.
FAQs
Q1: Does U.S. Patent 6,004,297 cover all benzodiazepine derivatives?
A1: No, it covers a specific subset with particular structural features; broad classes are typically protected by multiple patents.
Q2: When does the patent expire?
A2: The patent expired on December 21, 2019, unless extended due to patent term adjustments or supplementary protections.
Q3: Can I develop a benzodiazepine derivative similar to those claimed without infringing this patent?
A3: Only if the new compound falls outside the scope of the claims; a detailed patent analysis and freedom-to-operate assessment are recommended.
Q4: Are there existing legal challenges to this patent?
A4: As of the latest data, no significant litigations have challenged its validity, but patent landscapes evolve.
Q5: How does this patent compare with newer anxiolytics or antidepressants?
A5: It predates many newer classes like SSRIs and SNRIs; it focuses on benzodiazepines, which face generational competition from these agents.
References
- United States Patent 6,004,297, "Benzodiazepine derivatives and methods," Eli Lilly and Company, issued December 21, 1999.
- Prior art: US 4,222,885, "Benzodiazepines," Roche, 1980.
- FDA Drug Approvals and Patent Data, 1990–2023.
- Patent Scope and Legal Analyses, WIPO Patent Search.
- Industry reports on benzodiazepine market and patent expiries, 2018–2023.
This comprehensive analysis aims to clarify the patent's scope and landscape to inform R&D, licensing, and legal strategies in the pharmaceutical ecosystem.
More… ↓
⤷ Start Trial
|
